<DOC>
	<DOCNO>NCT01007435</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group study assess safety , disease remission , prevention structural joint damage patient early moderate severe rheumatoid arthritis treat tocilizumab monotherapy combination methotrexate , versus methotrexate alone . Patients randomize receive either ( A ) tocilizumab ( 8 mg/kg iv every 4 week ) plus placebo , ( B ) tocilizumab ( 8 mg/kg iv every 4 week ) plus methotrexate ( 7.5-20 mg po weekly ) , ( C ) tocilizumab ( 4 mg/kg iv every 4 week ) plus methotrexate ( 7.5-20 mg po weekly ) , ( D ) placebo plus methotrexate ( 7.5-20 mg po weekly ) . Patients group C D achieve low disease activity week 52 receive tocilizumab 8 mg/kg iv every 4 week . Anticipated time study treatment 104 week .</brief_summary>
	<brief_title>A Study Tocilizumab Monotherapy Combination With Methotrexate Versus Methotrexate Patients With Early Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient ≥ 18 year age . Rheumatoid arthritis ≤ 2 year duration . Disease Activity Score 28 ( DAS28 ) &gt; 3.2 . Swollen joint count ( SJC ) ≥ 4 66 joint , tender joint count ( TJC ) ≥ 6 68 joint . Rheumatoid factor ( RF ) and/or anti−cyclic citrullinated peptide ( antiCCP ) positive ( RF antiCCP negative &gt; 1 erosion require screening ) . Erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/h Creactive protein ( CRP ) ≥ 10 mg/L screening . Previous treatment tocilizumab . Previous treatment methotrexate biologic agent . Rheumatic autoimmune disease rheumatoid arthritis ( RA ) . History current inflammatory joint disease RA . Functional class IV define American College Rheumatology ( ACR ) Classification Functional Status RA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>